Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression
| Autor: | Masayuki Takeda, Kazuhiko Nakagawa, Kazuko Sakai, Hitomi Sakai, Kazuto Nishio |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry medicine.medical_treatment Mucosal melanoma Cancer Ipilimumab Immunotherapy Articles medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Cutaneous melanoma medicine 030211 gastroenterology & hepatology Neutrophil to lymphocyte ratio Nivolumab business medicine.drug Rare disease |
| Zdroj: | Mol Clin Oncol |
| ISSN: | 2049-9450 |
| Popis: | Anorectal melanoma is a rare disease with a poor prognosis and its response to immunotherapy remains poorly studied. The current study reports a case of recurrent anorectal melanoma in a 60-year-old woman that has exhibited a durable response to ipilimumab for >2 years. Given that the combination of nivolumab and ipilimumab was not approved for use in unresectable or metastatic melanoma at the time of presentation, the patient was initially treated with nivolumab monotherapy and switched to ipilimumab after nivolumab failure. The tumor was microsatellite stable, had an intermediate tumor mutation burden and was negative for programmed cell death-ligand-1 expression. However, the neutrophil-to-lymphocyte ratio in peripheral blood remained at |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|